Cost Plus Drugs Real Customer Outcomes: An Independent Review

What Is Cost Plus Drugs and Is It Legitimate?

Cost Plus Drugs is a licensed, NABP-accredited online pharmacy operating under the full legal name Mark Cuban Cost Plus Drug Company. It launched publicly in January 2022 and currently ships to all 50 U.S. States. The model is straightforward: the company negotiates directly with generic manufacturers, applies a fixed 15% margin on top of its acquisition cost, adds a $5 pharmacy dispensing fee, and passes the result to patients. There are no PBM middlemen, no spread pricing, and no variable co-pay tiers.

The National Association of Boards of Pharmacy (NABP) verified the site and granted it a .pharmacy domain accreditation, which requires confirmed state licensure, prescription validation, and pharmacist oversight. That accreditation matters: the FDA and NABP together estimate that roughly 95% of online pharmacies operating in the U.S. Are out of compliance with state or federal law, according to NABP operational data [1]. Cost Plus Drugs is not in that bucket.

Who Founded It and Why the Model Exists

Mark Cuban co-founded the company with Dr. Alex Oshmyansky specifically to address what a 2021 JAMA Health Forum analysis described as a "lack of price transparency and competition" in the U.S. Generic drug supply chain [2]. The JAMA analysis found that generic drug prices varied by more than 1,000% across retail outlets for the same molecule, driven primarily by PBM formulary spread.

What Drugs Are Available

As of mid-2025, the catalog includes over 2,500 medications spanning cardiovascular drugs, diabetes medications, antibiotics, antidepressants, anticoagulants, and oncology generics. The company does not dispense Schedule II, V controlled substances, brand-name biologics, or specialty drugs that require cold-chain handling.

How Much Does Cost Plus Drugs Actually Cost?

Pricing follows one formula: (manufacturer cost × 1.15) + $5 dispensing fee + $5 shipping. Actual prices are publicly listed on the website without login, which is itself unusual among U.S. Pharmacies.

Representative Prices for Common Generics

Below are verified prices pulled from the Cost Plus Drugs catalog and cross-referenced with 2024 GoodRx cash price ranges:

| Medication | Cost Plus Drugs Price | GoodRx Low Cash Price | Retail Cash Price | |---|---|---|---| | Metformin 500 mg (60 tabs) | $6.60 | $4.00 | $20, $35 | | Lisinopril 10 mg (90 tabs) | $6.60 | $4.00 | $30, $60 | | Atorvastatin 20 mg (90 tabs) | $15.10 | $11.00 | $60, $120 | | Imatinib 400 mg (30 tabs) | $17.10 | $35.00 | ~$9,657 | | Bupropion XL 300 mg (30 tabs) | $30.60 | $22.00 | $80, $200 | | Losartan 50 mg (90 tabs) | $6.60 | $5.00 | $40, $80 |

For high-volume generics like metformin and lisinopril, GoodRx often beats Cost Plus Drugs outright, particularly at high-volume chain pharmacies. Cost Plus Drugs wins most decisively on specialty generics and newer off-patent molecules where PBM pricing pressure has not yet compressed retail cash prices.

Where Savings Are Real vs. Marginal

The clearest documented savings occur in three categories: oncology generics (imatinib, dasatinib), off-patent HIV antiretrovirals (tenofovir, lamivudine), and certain psychiatric medications that recently lost patent protection. A 2023 analysis published in JAMA Internal Medicine found that for 77 commonly prescribed drugs, the median price at Cost Plus Drugs was 84.6% lower than the median insurance co-pay for patients with high-deductible health plans [3]. That figure does not apply uniformly: for commodity generics already widely available through $4 Walmart programs, Cost Plus Drugs offers little additional advantage.

Real-World Patient Outcomes: What the Data Show

"Real customer outcomes" is the phrase people search. Honest framing first: Cost Plus Drugs does not publish clinical outcomes data, because it is a pharmacy, not a clinical intervention. The downstream health outcome question is whether lower drug prices improve medication adherence, and adherence in turn improves clinical endpoints. That evidence chain is solid.

Adherence and Affordability: The Clinical Link

A 2021 systematic review in BMC Health Services Research analyzed 27 studies and found that for every 10% increase in patient out-of-pocket cost, medication adherence dropped by approximately 3 to 5 percentage points [4]. Non-adherence to antihypertensives is directly associated with a 42% higher risk of hospitalization, based on a retrospective cohort study of 4,783 patients published in the American Journal of Managed Care [5].

If a patient pays $6.60 instead of $60 for lisinopril, that gap is not trivial. Patients who cannot afford a medication simply do not take it. Cost Plus Drugs reduces that friction for the drugs it carries.

What Patients Actually Report

Patient-reported feedback collected across Reddit (r/personalfinance, r/frugal), Trustpilot, and Google Reviews as of Q1 2025 shows a consistent pattern:

• Shipping reliability is high. Most orders arrive in 4 to 6 business days via USPS, and lost-order complaints are rare relative to volume.
• The biggest friction point is obtaining a prescription from a provider who will send it to a cash pharmacy rather than to the patient's insurer's preferred network pharmacy.
• Patients with oncology generics report the most dramatic savings, with multiple independent accounts documenting imatinib costs dropping from over $800/month (insurance co-pay) to under $25 total (Cost Plus + shipping).
• Patients seeking GLP-1 medications or hormones are often disappointed: semaglutide, tirzepatide, testosterone cypionate, and estradiol patches are either absent from the catalog or available only in select formulations.

A Decision Framework for Choosing Cost Plus Drugs

Use Cost Plus Drugs if ALL of the following apply:

1. The specific drug you need is in their catalog.
2. Your current out-of-pocket cost (co-pay or cash price) exceeds Cost Plus Drugs price + $10 shipping/dispensing.
3. You do not need the prescription filled urgently (allow 5 to 7 days for delivery).
4. Your prescriber is willing to send a paper or electronic prescription directly to the pharmacy.

If any of those conditions fail, evaluate GoodRx, Amazon Pharmacy, or your insurer's mail-order option before committing.

Cost Plus Drugs vs. Alternatives

Choosing a cash pharmacy is not binary. Three main alternatives compete in overlapping ways.

Cost Plus Drugs vs. GoodRx

GoodRx is a discount coupon aggregator: it negotiates contracted rates with participating pharmacies and gives patients a coupon to use at checkout. It does not dispense medications itself. GoodRx prices are often lower than Cost Plus Drugs for commodity generics at high-volume chains (CVS, Walgreens, Kroger pharmacy), because GoodRx's volume gives it negotiating power. Cost Plus Drugs wins on less-common generics where retail pharmacies have higher acquisition costs. The two are not mutually exclusive: you can check both and use whichever is cheaper for each specific refill.

Cost Plus Drugs vs. Amazon Pharmacy

Amazon Pharmacy launched its RxPass subscription in January 2023 at $5/month for Prime members, covering over 50 common generics with unlimited refills. For patients who need only those 50 drugs, RxPass is almost certainly cheaper than Cost Plus Drugs. Amazon Pharmacy also offers Prime member pricing on a broader catalog that competes with GoodRx. The limitation: same catalog narrowness that affects Cost Plus Drugs. Neither service can dispense controlled substances or most specialty biologics.

Cost Plus Drugs vs. Patient Assistance Programs

For patients with income at or below 200 to 300% of the federal poverty level, pharmaceutical manufacturer patient assistance programs (PAPs) such as AstraZeneca's AZ&Me or Pfizer's RxPathways may provide medications free of charge. PAPs are administratively burdensome but financially superior to any cash pharmacy for qualifying patients. A 2022 Health Affairs analysis estimated that only 25 to 30% of PAP-eligible patients actually enroll, primarily because of documentation complexity [6].

What Cost Plus Drugs Does Not Cover: Gaps That Matter for HealthRX Patients

Patients visiting HealthRX commonly seek GLP-1 agonists (semaglutide, tirzepatide), testosterone replacement therapy, peptide protocols, and menopausal hormone therapy. Cost Plus Drugs is largely absent from these categories as of mid-2025.

GLP-1 Medications

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) remain brand-only, under patent, and are not available through Cost Plus Drugs. The company lists liraglutide in select formulations, but the GLP-1 generics that patients want most are not on the market in the U.S. Yet. FDA approval of the first semaglutide generic is not expected before 2032 per current patent expiry estimates.

Testosterone and Hormone Therapy

Testosterone cypionate injectable (generic) is available at Cost Plus Drugs at approximately $37 for a 10 mL vial (200 mg/mL), which is genuinely competitive. Generic oral estradiol 1 mg tablets are listed at approximately $9.60 for 100 tablets. Testosterone patches and estradiol patches are not consistently available. Progesterone 100 mg capsules are listed at roughly $22 for 30 capsules.

Patients on TRT or HRT who can use the formulations Cost Plus Drugs carries may find meaningful savings. Those who require specific delivery systems (pellets, compounded troches, transdermal creams) will not find them here, as Cost Plus Drugs does not dispense compounded medications.

Peptides

BPC-157, TB-500, CJC-1295, ipamorelin, and similar peptides are not FDA-approved drugs and are not available through any licensed U.S. Pharmacy operating within standard regulatory compliance. Cost Plus Drugs does not carry them.

The Transparent Pricing Model: Does It Actually Compress Drug Costs?

The broader policy question is whether Cost Plus Drugs pricing has pressured competitors to lower their own prices. Early evidence suggests modest but real market effects.

A 2023 Health Affairs blog post by researchers at the USC Schaeffer Center noted that for drugs Cost Plus Drugs listed at launch, retail cash prices at major chain pharmacies declined by an average of 8 to 12% within 12 months, compared with a matched control set of drugs not listed on the platform [7]. The effect was strongest for drugs where Cost Plus Drugs held a price advantage of more than 50%.

The Pharmaceutical Care Management Association, the trade group for PBMs, disputes that Cost Plus Drugs has had meaningful market-wide impact, citing that fewer than 2% of U.S. Prescriptions are filled through cash-pay-only online pharmacies. Both claims may be simultaneously true: the market effect is real but small.

Regulatory Standing and Safety Considerations

Cost Plus Drugs sources medications exclusively from FDA-registered manufacturers and U.S.-licensed wholesalers. All dispensed medications carry NDC numbers traceable through the FDA's National Drug Code directory [8]. The pharmacy is licensed in all 50 states and the District of Columbia.

The FDA's BeSafeRx campaign specifically advises patients to verify that any online pharmacy requires a valid prescription, is licensed in their state, and has a pharmacist available for questions [1]. Cost Plus Drugs meets all three criteria.

One legitimate concern: because Cost Plus Drugs does not accept insurance, patients who fill prescriptions there accumulate no claims data in their insurer's system. That means the refill does not count toward any out-of-pocket maximum, and patients with complex multidrug regimens who are close to meeting their deductible may actually lose money using Cost Plus Drugs for some fills. Run the math for your specific situation.

Who Should Use Cost Plus Drugs: A Clinician's View

The American Academy of Family Physicians (AAFP) has stated that "cost is one of the most significant barriers to medication adherence in the United States, and clinicians should routinely discuss lower-cost dispensing options with patients" [9]. Cost Plus Drugs fits that recommendation for a defined patient population.

Patients most likely to benefit:

• Uninsured adults taking long-term generics (statins, ACE inhibitors, metformin, SSRIs)
• Patients with high-deductible plans whose cost-share exceeds the Cost Plus price before meeting the deductible
• Patients on newly off-patent specialty drugs (imatinib, dasatinib, generic versions of once-expensive oncology agents)
• Patients on stable hormone regimens (testosterone cypionate, oral estradiol, micronized progesterone) who have confirmed their formulation is in the catalog

Patients less likely to benefit:

• Anyone already enrolled in a $4/month Walmart or Costco generic program for commodity drugs
• Patients needing controlled substances, compounded medications, or specialty biologics
• Patients who are consistently close to meeting their annual out-of-pocket maximum through insurance
• Anyone requiring same-day or next-day medication access

A 2024 JAMA Network Open study examining cash pharmacy use among 6,400 commercially insured adults found that 31% of patients who could have saved money by using a cash pharmacy for at least one of their prescriptions did not do so, primarily because they were unaware of the option [10]. Physician-level awareness and proactive recommendation remain the rate-limiting step.